| 11633408 |
Prevention of adverse effects caused by CD3 specific binding domains |
Dirk Nagorsen, Juergen Scheele |
2023-04-25 |
| 11597766 |
Treatment of acute lymphoblastic leukemia |
Evelyn Degenhard |
2023-03-07 |
| 11084876 |
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains |
Peter Kufer, Dirk Nagorsen, Juergen Scheele, Matthias Klinger, Patrick Hoffmann +2 more |
2021-08-10 |
| 11079381 |
Risk-stratification of B-precursor acute lymphoblastic leukemia patients |
Peter Kufer, Shilpa Alekar |
2021-08-03 |
| 11053318 |
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
Peter Kufer, Roman Kischel, Marion Subklewe, Christina Heitmueller |
2021-07-06 |
| 10696744 |
Means and methods for treating DLBCL |
Dirk Nagorsen, Juergen Scheele |
2020-06-30 |
| 10662243 |
Dosage regimen for administering a CD19XCD3 bispecific antibody |
Dirk Nagorsen, Peter Kufer, Patrick Bauerle |
2020-05-26 |
| 10130638 |
Prevention of adverse effects caused by CD3 specific binding domains |
Dirk Nagorsen, Juergen Scheele |
2018-11-20 |
| 9688760 |
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains |
Peter Kufer, Dirk Nagorsen, Juergen Scheele, Matthias Klinger, Patrick Hoffmann +2 more |
2017-06-27 |
| 9486475 |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
Peter Kufer, Dirk Nagorsen, Juergen Scheele, Matthias Klinger, Patrick Hoffmann +2 more |
2016-11-08 |
| 9192665 |
Means and methods for treating DLBCL |
Dirk Nagorsen, Juergen Scheele |
2015-11-24 |
| 8840888 |
Dosage regimen for administering a CD19XCD3 bispecific antibody |
Dirk Nagorsen, Peter Kufer, Patrick Baeuerle |
2014-09-23 |
| 7700299 |
Method for predicting the response to a treatment |
Joachim Moecks, Andreas Strauss |
2010-04-20 |
